Try our mobile app

AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ™ (upadacitinib) in Atopic Dermatitis

Published: 2020-10-29 06:05:00 ET
<<<  go to ABBV company page

-- New RINVOQ analyses from the Measure Up 1 and 2 monotherapy studies show improvements in additional measures of skin clearance, itch and quality of life in adult and adolescent patients with moderate to severe atopic dermatitis[1]

-- Earlier this year, AbbVie announced top-line data from the Measure Up 1 and 2 studies showing upadacitinib (15 mg or 30 mg) met the co-primary endpoints and all secondary endpoints (p